#netter1 résultats de recherche

In our discussion with @helops79 and @ProfKHerrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS): - #COMPETE - #COMPOSE - #NETTER1 - #NETTER2 #OncTwitter #MedTwitter #gism

OncBrothers's tweet image. In our discussion with @helops79 and @ProfKHerrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS): 

- #COMPETE
- #COMPOSE
- #NETTER1
- #NETTER2 

#OncTwitter #MedTwitter #gism

PRRT - Radioligand Rx options in Neuroendocrine Tumors (NETs) with @helops79 & Ken Herrmann ✅ Different molecules ✅ Squencing ✅ Scans Full discussion: oncbrothers.com/net-prrt-2025 - m.youtube.com/watch?si=mYVB6… - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter



VIDEO: NETTER-1 Phase III Trial Results Meet Primary Endpoint oncologytube.com/video/netter-1… @MoffittNews #GI17 #netter1 @ASCOPost

oncologytube's tweet image. VIDEO: NETTER-1 Phase III Trial Results Meet Primary Endpoint oncologytube.com/video/netter-1… @MoffittNews #GI17 #netter1 @ASCOPost

Datos finales de eficacia y seguridad del estudio #NETTER1 presentados en el congreso #WorldGI2021. ➕OS 36 vs 48 meses (p 0.3) ➕36% crossover ➕1.8% MDS ➕5.4% toxicidad renal @NievesM42607618 @DrMunozdeNova @endobioinfo @GreyVB @myESMO @_SEOM @Netespana

GrupoGetne's tweet image. Datos finales de eficacia y seguridad del estudio #NETTER1 presentados en el congreso #WorldGI2021.

➕OS 36 vs 48 meses (p 0.3)
➕36% crossover
➕1.8% MDS
➕5.4% toxicidad renal

@NievesM42607618 @DrMunozdeNova @endobioinfo @GreyVB @myESMO @_SEOM @Netespana

Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 ➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄 ➡️ no new long term safety signals for MDS and renal toxicity ⏭ what is the value of PRRT re-treatment? @myESMO

GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO


#Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal #NETTER1 study with targeted #RadioligandTherapy #Lutathera 1stoncology.com/blog/novartis-…


#Therametrics subsidiary has been selected to extend international #PhaseIII clinical trial #Netter1 ow.ly/CtP1Y


In our discussion with @helops79 and @ProfKHerrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS): - #COMPETE - #COMPOSE - #NETTER1 - #NETTER2 #OncTwitter #MedTwitter #gism

OncBrothers's tweet image. In our discussion with @helops79 and @ProfKHerrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS): 

- #COMPETE
- #COMPOSE
- #NETTER1
- #NETTER2 

#OncTwitter #MedTwitter #gism

PRRT - Radioligand Rx options in Neuroendocrine Tumors (NETs) with @helops79 & Ken Herrmann ✅ Different molecules ✅ Squencing ✅ Scans Full discussion: oncbrothers.com/net-prrt-2025 - m.youtube.com/watch?si=mYVB6… - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter



Datos finales de eficacia y seguridad del estudio #NETTER1 presentados en el congreso #WorldGI2021. ➕OS 36 vs 48 meses (p 0.3) ➕36% crossover ➕1.8% MDS ➕5.4% toxicidad renal @NievesM42607618 @DrMunozdeNova @endobioinfo @GreyVB @myESMO @_SEOM @Netespana

GrupoGetne's tweet image. Datos finales de eficacia y seguridad del estudio #NETTER1 presentados en el congreso #WorldGI2021.

➕OS 36 vs 48 meses (p 0.3)
➕36% crossover
➕1.8% MDS
➕5.4% toxicidad renal

@NievesM42607618 @DrMunozdeNova @endobioinfo @GreyVB @myESMO @_SEOM @Netespana

Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 ➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄 ➡️ no new long term safety signals for MDS and renal toxicity ⏭ what is the value of PRRT re-treatment? @myESMO

GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO


VIDEO: NETTER-1 Phase III Trial Results Meet Primary Endpoint oncologytube.com/video/netter-1… @MoffittNews #GI17 #netter1 @ASCOPost

oncologytube's tweet image. VIDEO: NETTER-1 Phase III Trial Results Meet Primary Endpoint oncologytube.com/video/netter-1… @MoffittNews #GI17 #netter1 @ASCOPost

#Therametrics subsidiary has been selected to extend international #PhaseIII clinical trial #Netter1 ow.ly/CtP1Y


VIDEO: NETTER-1 Phase III Trial Results Meet Primary Endpoint oncologytube.com/video/netter-1… @MoffittNews #GI17 #netter1 @ASCOPost

oncologytube's tweet image. VIDEO: NETTER-1 Phase III Trial Results Meet Primary Endpoint oncologytube.com/video/netter-1… @MoffittNews #GI17 #netter1 @ASCOPost

Datos finales de eficacia y seguridad del estudio #NETTER1 presentados en el congreso #WorldGI2021. ➕OS 36 vs 48 meses (p 0.3) ➕36% crossover ➕1.8% MDS ➕5.4% toxicidad renal @NievesM42607618 @DrMunozdeNova @endobioinfo @GreyVB @myESMO @_SEOM @Netespana

GrupoGetne's tweet image. Datos finales de eficacia y seguridad del estudio #NETTER1 presentados en el congreso #WorldGI2021.

➕OS 36 vs 48 meses (p 0.3)
➕36% crossover
➕1.8% MDS
➕5.4% toxicidad renal

@NievesM42607618 @DrMunozdeNova @endobioinfo @GreyVB @myESMO @_SEOM @Netespana

Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 ➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄 ➡️ no new long term safety signals for MDS and renal toxicity ⏭ what is the value of PRRT re-treatment? @myESMO

GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO
GillSharlene's tweet image. Long term OS and safety data from the NETTER1 trial: PRRT in midgut NET #WorldGI2021 
➡️ significant PFS but non-significant OS d/t crossover - not a surprise 🙄
➡️ no new long term safety signals for MDS and renal toxicity 
⏭ what is the value of PRRT re-treatment?  @myESMO


In our discussion with @helops79 and @ProfKHerrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS): - #COMPETE - #COMPOSE - #NETTER1 - #NETTER2 #OncTwitter #MedTwitter #gism

OncBrothers's tweet image. In our discussion with @helops79 and @ProfKHerrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS): 

- #COMPETE
- #COMPOSE
- #NETTER1
- #NETTER2 

#OncTwitter #MedTwitter #gism

PRRT - Radioligand Rx options in Neuroendocrine Tumors (NETs) with @helops79 & Ken Herrmann ✅ Different molecules ✅ Squencing ✅ Scans Full discussion: oncbrothers.com/net-prrt-2025 - m.youtube.com/watch?si=mYVB6… - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter



Loading...

Something went wrong.


Something went wrong.


United States Trends